OQS
VNDA icon

Occudo Quantitative Strategies’s Vanda Pharmaceuticals VNDA Stock Holding History

Occudo Quantitative Strategies’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-57,769
Closed -$237K – 1019
2024
Q1 		$237K Buy
+57,769
New +$231K 0.04% 544
2022
Q4 		– Sell
-65,773
Closed -$650K – 1403
2022
Q3 		$650K Buy
+65,773
New +$694K 0.05% 577

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Occudo Quantitative Strategies's VNDA Position: Q2 2024 in Review

Occudo Quantitative Strategies sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 57,769 shares — an estimated $237K sold.

Occudo Quantitative Strategies first reported a position in VNDA in Q3 2022 and held it in 2 quarters. The position peaked at $650K in Q3 2022. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

  • Occudo Quantitative Strategies reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 57,769 Vanda Pharmaceuticals shares in Q2 2024, an estimated $237K.
  • Occudo Quantitative Strategies first reported a position in Vanda Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Occudo Quantitative Strategies's Vanda Pharmaceuticals position peaked at $650K in Q3 2022.
  • 148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.